APA (7th ed.) Citation

Narek Shaverdian, M., Michael Offin, M., Annemarie F. Shepherd, M., Matthew D. Hellmann, M., Daniel R. Gomez, M., Jamie E. Chaft, M., & Andreas Rimner, M. (2021). Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC. Elsevier.

Chicago Style (17th ed.) Citation

Narek Shaverdian, MD, MD Michael Offin, MD Annemarie F. Shepherd, MD Matthew D. Hellmann, MD Daniel R. Gomez, MD Jamie E. Chaft, and MD Andreas Rimner. Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC. Elsevier, 2021.

MLA (8th ed.) Citation

Narek Shaverdian, MD, et al. Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC. Elsevier, 2021.